Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by BearDownAZon Apr 11, 2013 3:27pm
325 Views
Post# 21243387

RE: Abstract from upcoming EAS conference in June

RE: Abstract from upcoming EAS conference in June

BTW, RVX lists this conference on their events website, but the only relevant abstract I can find is a presentation by Steve Nissen entitled "Therapeutic options to induce regression of coronary atherosclerosis"

I also just appreciated that end of May, beginning of June are two back to back lipid/athero conferences that RVX is attending. 1) National Lipid Association conference in Las Vegas 5/30/13 to 6/2/13 and 2) European Atherosclerosis Society Congress 6/2/13 to 6/5/13. This is interesting because these conferences would come immediately after the proposed 5/28/13 meeting/vote on the SPINCO arrangment. 

Could be that RVX would wait until these two meetings, which occur AFTER the vote, to announce anything significant. Of course, Don said no ASSURE topline data until end of June. But there could be some very promising teasers released. 

I still anticipate RVX revelaing something SUSTAIN related at ATVB in the beginning of May. But now I am thinking that somethiing significant will be presented ASSURE related at the end of May/beginning of June.

 

Bullboard Posts